Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.75 |
| ▸ | MEN1 | O00255 | 2/20 | 0.73 |
| ▸ | HTT | P42858 | 2/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.73 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.68 |
| ▸ | TP53 | P04637 | 2/20 | 0.61 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.61 |
| ▸ | MMP2 | P08253 | 1/20 | 0.57 |
| ▸ | MMP9 | P14780 | 1/20 | 0.57 |
| ▸ | COMT | P21964 | 1/20 | 0.57 |
| ▸ | MMP8 | P22894 | 1/20 | 0.57 |
| ▸ | MMP13 | P45452 | 1/20 | 0.57 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15424140 | 0.94 | MEN1 (0.73) | MAPTMEN1HTTKMT2AKDM4E | |
| SCHEMBL5820403 | 0.89 | MAPT (0.74) | MAPTMEN1HTTKMT2AKDM4E | |
| SCHEMBL15424155 | 0.87 | MEN1 (0.67) | MAPTMEN1HTTKMT2AKDM4E | |
| SCHEMBL13679611 | 0.86 | MEN1 (0.74) | MAPTMEN1HTTKMT2AKDM4E | |
| SCHEMBL15424152 | 0.86 | MAPT (0.65) | MAPTMEN1HTTKMT2AKDM4E | |
| SCHEMBL20145790 | 0.86 | MEN1 (0.62) | MAPTMEN1HTTKMT2AKDM4E | |
| SCHEMBL15424141 | 0.86 | MAPT (0.60) | MAPTMEN1HTTKMT2AKDM4E | |
| SCHEMBL14642442 | 0.85 | MEN1 (0.79) | MAPTMEN1HTTKMT2AKDM4E | |
| SCHEMBL13679581 | 0.85 | MEN1 (0.69) | MAPTMEN1HTTKMT2AKDM4E | |
| SCHEMBL14642412 | 0.84 | MEN1 (1.00) | MAPTMEN1HTTKMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170349573-A1 | HEDGEHOG ANTAGONISTS HAVING ZINC BINDING MOIETIES | CURIS INC (US) | 2017-12-07 | — | — | US | disclosed |
| US-9708299-B2 | Hedgehog antagonists having zinc binding moieties | GENENTECH, INC. (US) | 2017-07-18 | — | — | US | disclosed |
| US-9708299-B2 | Hedgehog antagonists having zinc binding moieties | GENENTECH, INC. (US) | 2017-07-18 | — | — | US | disclosed |
| US-20140018368-A1 | HEDGEHOG ANTAGONISTS HAVING ZINC BINDING MOIETIES | GENETECH, INC. (US) | 2014-01-16 | — | — | US | disclosed |
| US-20140018368-A1 | HEDGEHOG ANTAGONISTS HAVING ZINC BINDING MOIETIES | GENETECH, INC. (US) | 2014-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170349573-A1 | HEDGEHOG ANTAGONISTS HAVING ZINC BINDING MOIETIES | GLI1, SHH, HDAC1 | MAPT 3245/4885MEN1 3364/4885HTT 1409/4885 |
| US-20140018368-A1 | HEDGEHOG ANTAGONISTS HAVING ZINC BINDING MOIETIES | GLI1, SHH, HDAC1 | MAPT 3245/4885MEN1 3364/4885HTT 1409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.